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Background: Both pulmonary arterial stiffening and systemic arterial stiffening have been 
described in COPD. The aim of the current study was to assess pulse wave velocity (PWV) 
within these two arterial beds to determine whether they are separate or linked processes.
Materials and methods: In total, 58 participants with COPD and 21 healthy volunteers (HVs) 
underwent cardiac magnetic resonance imaging (MRI) and were tested with a panel of relevant 
biomarkers. Cardiac MRI was used to quantify ventricular mass, volumes, and pulmonary (pulse 
wave velocity [pPWV] and systemic pulse wave velocity [sPWV]).
Results: Those with COPD had higher pPWV (COPD: 2.62 vs HV: 1.78 ms−1, 
p=0.006), higher right ventricular mass/volume ratio (RVMVR; COPD: 0.29 vs HV: 
0.25 g/mL, p=0.012), higher left ventricular mass/volume ratio (LVMVR; COPD: 0.78 vs 
HV: 0.70 g/mL, p=0.009), and a trend toward a higher sPWV (COPD: 8.7 vs HV: 7.4 ms−1, 
p=0.06). Multiple biomarkers were elevated: interleukin-6 (COPD: 1.38 vs HV: 0.58 pg/mL, 
p=0.02), high-sensitivity C-reactive protein (COPD: 6.42 vs HV: 2.49 mg/L, p=0.002), 
surfactant protein D (COPD: 16.9 vs HV: 9.13 ng/mL, p=0.001), N-terminal pro-brain 
natriuretic peptide (COPD: 603 vs HV: 198 pg/mL, p=0.001), and high-sensitivity troponin 
I (COPD: 2.27 vs HV: 0.92 pg/mL, p,0.001). There was a significant relationship between 
sPWV and LVMVR (p=0.01) but not pPWV (p=0.97) nor between pPWV and RVMVR 
(p=0.27).
Conclusion: Pulmonary arterial stiffening and systemic arterial stiffening appear to be dis-
connected and should therefore be considered independent processes in COPD. Further work 
is warranted to determine whether both these cause an increased morbidity and mortality and 
whether both can be targeted by similar pharmacological therapy or whether different strategies 
are required for each.
Keywords: pulmonary vascular, cardiovascular, COPD, arterial compliance, ventricular 
function
Introduction
Despite being a disease of the pulmonary parenchyma, COPD is associated with signifi-
cant cardiac morbidity and mortality, with up to 43% of mortality in COPD secondary 
to cardiovascular causes.1–3 Even in the absence of pulmonary hypertension, those with 
COPD demonstrate right ventricular (RV) dysfunction,4,5 and diastolic and systolic left 
heart failures are present in .20% of those with moderate-to-severe COPD.6,7
Arteriosclerosis is the stiffening of the arterial wall and is predominantly a 
result of aging and rising mean arterial pressure in both the systemic and pulmonary 
circulation.8–11 An increase in arterial stiffening leads to an increased afterload and 
an inefficient energy transfer from the ventricles to the vasculature, resulting in an 
increased cardiac workload.12,13 Increased stiffening of both the systemic and pulmonary 
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circulation has been described in COPD, independent of 
traditional risk factors.14,15 Due to its adverse hemodynamic 
effects, arterial stiffening is a well-established risk factor 
for future cardiovascular mortality.16 Multiple studies have 
demonstrated systemic arterial stiffening in those with 
COPD when compared with matched smokers and for this 
stiffening to correlate with the percentage of emphysema.14,17 
Several studies have also shown COPD therapy to result in 
an improvement in arterial stiffness, although this observa-
tion has not been consistent across all studies.18–20 Pulmonary 
arterial stiffness has also been shown to correlate with exer-
cise capacity and right heart function in COPD.21 It has also 
been shown that those with COPD who are taking statins 
have lower pulmonary pressures on right heart catheteriza-
tion compared with those not on statins and that statins are 
associated with improved functional capacity and lower 
mortality in COPD.22–24 Given that statins improve systemic 
cardiovascular disease and mediate adverse vascular remod-
eling in atherosclerosis,25,26 it may thus be posited that the 
disease process afflicting the pulmonary arteries and aorta 
may simply be the same pathological process resulting from 
a COPD-induced accelerated vascular degeneration.
Thus, the aim of the current study was to examine the 
association between aortic and pulmonary arterial stiffening 
using pulse wave velocity (PWV) and their effects on cardiac 
remodeling with the hypotheses that 1) aortic stiffening and 
pulmonary stiffening occur in parallel; 2) inflammatory mark-
ers would explain this interaction; and 3) elevated PWV would 
be associated with adaptive ventricular remodeling with an 
increased ventricular mass to end diastolic volume ratio.
Materials and methods
Between July 2014 and May 2016, participants were 
recruited from primary and secondary care clinics and from 
community-based spirometry and research databases. Inclu-
sion criteria for the study were the following: 40–85 years of 
age with a diagnosis of COPD, based on the current Global 
Initiative for Chronic Obstructive Lung Disease guidelines 
of postbronchodilator forced expiratory volume in 1 second/
forced vital capacity ,0.7 with a history of smoking.27 Exclu-
sion criteria were the following: history of cardiac condition, 
including but not limited to ischemic heart disease, valvular 
disease (mild functional regurgitation allowed), arrhythmia, 
cardiomyopathy, congestive cardiac failure, or congenital 
cardiac disease; previous cardiac or thoracic operation; 
other coexistent lung condition; connective tissue disease 
or systemic vasculitis; severe renal impairment (epidermal 
growth factor receptor ,30 mL/min); or contraindication for 
magnetic resonance imaging (MRI). All recruited participants 
underwent a screening echocardiogram to exclude sig-
nificant silent left ventricular systolic dysfunction (ejection 
fraction ,45%).
In total, 104 participants with COPD were screened with 
37 excluded due to either coexistent coronary artery disease, 
atrial fibrillation, prior thoracotomy, coexistent lung condi-
tion, left ventricular systolic dysfunction on echo, or no 
history of smoking. This left 67 participants in the cohort. 
Of these, 56 participants were included in the final analysis 
(6 participants were excluded due to incomplete scan second-
ary to claustrophobia, 1 due to a history of metal fragments in 
the orbits not picked up in screening, and 4 due to inadequate 
image quality for analysis). All the participants gave written 
informed consent for the study that was conducted in accor-
dance with the Declaration of Helsinki and was approved by 
the East of Scotland Research Ethics Committee 1 (Reference 
Number: 14/ES/0034).
A healthy control (HC) group was recruited with the age 
and sex of them approximately matched to the COPD cohort, 
with no prior history of cardiac or pulmonary pathology.
All COPD participants underwent spirometry, single 
breath diffusion (diffusing capacity of the lungs for carbon 
monoxide [DLCO]), a 6-minute walk test (6MWT), and a 
cardiac MRI on the same day. All HCs underwent a cardiac 
MRI. Spirometry, DLCO, and 6MWT were performed as per 
European Respiratory Society/American Thoracic Society 
guidelines.28,29 The blood samples of all the participants were 
taken at the time of their attendance for the MRI scan.
MrI
Images were acquired on a 32–radiofrequency RF cardiac 
receiver channel, 3-Tesla MRI scanner (Prisma; Siemens 
Medical Solutions, Erlangen, Germany). A three-plane 
localizer was first obtained, following which 4-chamber, 
2-chamber, and short-axis localizers of the heart were 
obtained. An axial half-Fourier acquisition turbo spin echo 
stack was acquired of the chest.
From these, a balanced steady-state free precession 
(bSSFP) stack was performed in breath-hold from the atrio-
ventricular ring to the apex. To plan the main pulmonary 
artery (MPA) phase contrast sequence, a bSSFP sequence 
of the RV outflow tract was performed following which an 
orthogonal plane was acquired to optimally visualize the 
MPA and pulmonary valve. A bSSFP sequence was then 
performed through the MPA slice and was positioned mid-
way between the valve and the bifurcation of the pulmonary 
artery in order to avoid both structures throughout the cardiac 
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cycle. A free-breathing phase contrast sequence (slice thick-
ness =6 mm, time to relaxation/time to echo (TR/TE) =12/4 
ms, number of averages =1, phases =80, velocity encoding 
=150 cm/s, bandwidth/pixel =340 Hz, flip angle =15°, field 
of view =320×320 mm2, matrix =512×512) was then per-
formed in the same position as previously described.30 For 
aortic PWV measurement, a two-dimensional gradient echo 
(fast low-angle shot [FLASH] was first acquired of the aorta 
in a “candy stick” double-oblique orientation (parameters: 
TR/TE =40/1.2 ms; flip angle =15°, slice thickness =8 mm, 
23 cardiac phases, number of averages =1, a pixel size of 
1.5×1.5 mm2, bandwidth =475 Hz/pixel). Two-phase contrast 
sequences were then obtained, the first positioned through the 
aortic arch at the level of the pulmonary bifurcation and the 
second slice placed through the proximal abdominal aorta just 
distal to the aortic hiatus. The same phase contrast sequence 
was used as for the pulmonary PWV measurement. 
Image analysis
The images were exported with image analysis performed by 
using CVI 42 (Circle Cardiovascular Imaging Inc., Calgary, 
Alberta, Canada). 
Ventricular quantification
Epicardial and endocardial contours were drawn around the 
right ventricle at end systole and end diastole. Trabeculae 
were included in the mass measurement and excluded from 
the volume calculation. The septum was treated as belonging 
to the left ventricle and was excluded from the RV mass. RV 
mass and volumes were normalized to height1.7.
Pulmonary PWV
For the time component, the phase and magnitude images 
were pulled up side by side. A contour was manually 
drawn around the perimeter of the vessel, then propagated 
throughout the cardiac cycle, and corrected as when auto-
matic contouring led to erroneous boundaries. The program 
then automatically calculated area, flow, and velocity data, 
which were exported to Excel 2010 (Microsoft Corporation, 
Redmond, WA, USA). The area and flow were plotted against 
one another during early systole, which was defined as the 
time period in systole during which both the vessel area and 
flow were simultaneously increasing. The PWV was then 
calculated as described by Davies et al:31
 
PWV =
∆
∆
Q
A
∑
∑
2
2
where Q =vessel flow and A=vessel area.
aortic PWV
The distance was measured along the aorta between the two 
analysis planes (Δx value) using candy stick FLASH and the 
time delay calculated as the time delay between the arrival 
of the foot of the pulse wave at the ascending aorta and 
abdominal aorta. To calculate the latter, the flow curves from 
the ascending thoracic aorta and the abdominal aorta were 
plotted, and the time to the systolic upstroke of the waves 
was then calculated. The arrival time of the flow wave was 
identified as the intersection between the systolic upstroke 
and baseline flow. The systolic upstroke was calculated as 
the line through the data points lying between 20% and 80% 
of the maximum flow rate.32 The baseline was the horizontal 
line at minimum velocity before systole. Pulse wave was 
calculated using the following equation:
 
TT 
d
t
PWV = ∆
∆
where TT stands for transit time, d stands for distance 
between the imaging planes, and t stands for time of systolic 
upstroke arrival.
Biomarkers
In order to better understand the links between COPD, vas-
cular stiffening, and cardiac remodeling, several families of 
biomarkers were assessed: 1) connective tissue markers – 
carboxymethyllysine (CML), matrix metalloproteinase-9 
(MMP-9), and fibroblast growth factor-23 (FGF-23); 
2) inflammatory markers – high-sensitivity C-reactive protein 
(hsCRP), interleukin-6 (IL-6), and fibrinogen; 3) pulmonary 
markers – club cell secretory protein-16 (CC-16) and surfac-
tant protein D (SPD); 4) cardiac markers – high-sensitivity 
troponin I (hsTrop I) and N-terminal pro-brain natriuretic 
peptide (NT-proBNP); and 5) lipid markers – total cholesterol 
(TC), high-density lipoprotein (HDL), low-density lipopro-
tein (LDL), and triglycerides.
For this analysis, blood samples were drawn into 3×4 mL 
EDTA tubes, which were then centrifuged at 2,000× g at 
room temperature for 15 minutes before the plasma from 
this was removed and then stored at −80°C. All the samples 
were stored until the study was completed and then analyzed 
en bloc. Table S1 presents the details of the manufacturers 
and interassay (plate-to-plate) and intra-assay coefficients 
of variations.
statistics
Descriptive statistics were used for the analysis of the 
demographic and clinical features of the cohorts with data 
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expressed as mean ± SD. Normality and equality of variances 
of the variables were tested. An independent sample t-test 
was used to compare the differences in continuous variables 
between the HCs and COPD cohort. χ2, Fisher’s exact, and 
Mann–Whitney U tests were used as appropriate to compare 
differences in ordinal and nominal data between the groups. 
Pearson or Spearman rank coefficients were used to assess the 
correlation between aortic and pulmonary PWV and to look 
at the correlates of both of these with baseline demographic, 
spirometric, and MRI factors in the COPD cohort. Multiple 
linear regression analysis was performed with systemic pulse 
wave velocity (sPWV) and pulmonary pulse wave velocity 
(pPWV) entered separately as the dependent variables, with 
those factors which were (p,0.1) in single variable analysis 
entered as independent variables. All data were analyzed using 
SPSS package (Version 21.0; IBM Corporation, Armonk, NY, 
USA). Significance was assumed when p,0.05.
Results
In total, 56 COPD patients (67.4±9.0 years, 55% male) and 
20 HCs (60.4±5.1, 48% male) completed the study proto-
col. Despite approximate age and sex matching, those with 
COPD were significantly older (p,0.001) and had a higher 
body mass index (BMI; COPD: 26.8±5.3 kg/m2 vs HC: 
24.6±2.5 kg/m2, p=0.02). While those with COPD had a 
significantly higher prevalence of hypertension, there was no 
significant difference in blood pressure or pulse pressure due 
to a higher prevalence of antihypertensive medication pre-
scription. Table 1 presents the full baseline characteristics.
Those with COPD demonstrated a significantly higher 
pulmonary PWV (COPD: 2.6±1.3 ms−1 vs HC: 1.8±0.7 ms−1, 
p=0.006) and a trend toward a higher aortic PWV (COPD: 
8.7±2.7 ms−1 vs HC: 7.4±2.1 ms−1, p=0.06). Compared with 
the HCs, those with COPD had a significantly lower RV stroke 
volume (COPD: 31.7±7.0 mL/m1.7 vs HC: 36.6±5.9 mL/m1.7, 
p=0.007) and a higher RV mass/volume ratio (RVMVR; 
COPD: 0.29±0.05 g/mL vs HC: 0.25±0.04 g/mL, p=0.012). 
Those with COPD also had a significantly higher left ven-
tricular mass/volume ratio (LVMVR; COPD 0.78±0.13 g/mL 
vs HC: 0.70±0.09 g/mL, p=0.009; see Table 2 for full ven-
tricular and pulmonary arterial parameters).
In those with COPD, pulmonary PWV was correlated with 
percentage predicted total lung capacity (ρ=0.28, p=0.046), 
inversely correlated with BMI (ρ=−0.28, p=0.04), and cor-
related with increasing diastolic blood pressure (ρ=0.36, 
p=0.01) with a trend toward a positive correlation with 
percentage predicted residual lung volume (ρ=0.25, p=0.08; 
see Table S2 for full correlates). Applying a conservative 
Bonferroni correction for multiple comparisons would result 
in a significance level of p,0.0008, with none of the variables 
meeting this level. On multiple-variable backward linear 
regression, diastolic blood pressure (ß=0.28, p=0.035) and 
percentage predicted total lung capacity (ß=0.30, p=0.028) 
remained significantly associated with pPWV.
In comparison, aortic PWV showed a significant asso-
ciation with age (ρ=0.47, p,0.001), systolic blood pressure 
(ρ=0.32, p=0.02), and percentage predicted transfer coeffi-
cient for carbon monoxide (KCO) (ρ=0.43, p=0.001) and a 
trend toward a significant association with percentage pre-
dicted DLCO (ρ=0.27, p=0.050) and pulse pressure (ρ=0.25 
Table 1 Demographics of the COPD and healthy control cohorts
Demographics Healthy 
controls
COPD 
cohort
p-value
n 20 56
age (years) 60.1±4.9 67.5±9.3 ,0.001
sex (male) 9 (45%) 29 (52%) 0.60
BMI (kg/m2) 24.6±2.5 26.8±5.3 0.02
heart rate (bpm) 64.4±12.1 74.0±20.7 0.061
systolic BP (mmhg) 128.5±13.7 130.8±20.4 0.65
Diastolic BP (mmhg) 75.0±7.9 75.1±8.6 0.95
Pulse pressure (mmhg) 53.5±9.4 55.7±18.7 0.63
spO2 98.4±1.3 96.3±2.5 0.001
hypertension 2 (10%) 24 (43%) 0.012
hypercholesterolemia 3 (15%) 3 (5%) 0.18
Diabetes 0 (0%) 9 (16%) 0.1
smoking status
Current smoker 2 (10%) 17 (30%) 0.08
ex-smoker 7 (35%) 39 (70%) 0.009
never smoker 11 (55%) 0 (0%) ,0.001
Pack-years 4.92±7.5 48.5±23.6 ,0.001
Medications
aspirin 1 (5%) 9 (16%) 0.28
β-blocker 1 (5%) 3 (5%) 1
Diuretic 0 (0%) 9 (16%) 0.10
Calcium channel blocker 1 (5%) 15 (27%) 0.055
aCei/arB 0 (0%) 8 (14%) 0.10
statin 4 (20%) 14 (25%) 0.77
gOlD (FeV1) status
I 11 (20%)
II 31 (55%)
III 13 (23%)
IV 1 (2%)
mMrC grade
0 5 (9%)
1 26 (46%)
2 13 (23%)
3 10 (18%)
4 2 (4%)
Abbreviations: aCei, angiotensin converting enzyme inhibitor; arB, angiotensin 
receptor blocker; BMI, body mass index; BP, blood pressure; FeV1, forced expiratory 
volume in 1 second; gOlD, global Initiative for Chronic Obstructive lung Disease; 
mMRC, modified Medical Research Council.
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p=0.067). Applying a conservative Bonferroni correction for 
multiple comparisons would result in a significance level of 
p,0.0008, as a result of which only age would remain a sig-
nificant correlate of sPWV. On linear regression, age (ß=0.30, 
p=0.02), systolic blood pressure (ß=0.27, p=0.04), and 
percentage predicted KCO (ß=0.37, p=0.003) all remained 
significantly associated with aortic PWV.
sPWV was significantly associated with LVMVR 
(ρ=0.34, p=0.01), while no such correlation was found 
between pPWV and RVMVR (ρ=−0.15, p=0.27). Similarly, 
there was no significant association between aortic and pul-
monary PWV (ρ=−0.004, p=0.97; Figure 1). 
Those with COPD showed significantly higher levels of 
the following: inflammatory markers IL-6 (COPD: 1.38± 
1.38 pg/mL vs healthy volunteers [HVs]: 0.58±0.66 pg/mL, 
p=0.018) and hsCRP (COPD: 6.42±7.68 mg/L vs HV: 
2.49±2.84 mg/L, p=0.002); connective tissue markers 
MMP-9 (COPD: 121±72 ng/mL vs HV: 50±19 ng/mL, 
p,0.001); lung tissue marker SPD (COPD: 16.9±12.7 ng/mL 
vs HV: 9.13±5.41 ng/mL, p=0.001); and cardiac markers NT-
proBNP (COPD: 603±839 pg/mL vs HV: 198±165 pg/mL, 
p=0.001) and hsTrop I (COPD: 2.27±1.90 pg/mL vs HV: 
0.92±0.49 pg/mL, p,0.001).
No significant difference was found in FGF-23, CC-16, 
CML, fibrinogen, cholesterol, HDL, or LDL (p.0.05 for all). 
In those with COPD, there was a weak correlation 
between pPWV and hsCRP (ρ=−0.28, p=0.04), TC (ρ=0.28, 
p=0.044), and NT-proBNP (ρ=0.28, p=0.048). However, on 
linear regression accounting for diastolic blood pressure, the 
significance of these was lost. For sPWV, there was a weak 
correlation with CC-16 (ρ=0.31, p=0.028), TC (ρ=0.33, 
p=0.019), and LDL (ρ=0.32, p=0.023). However, on linear 
regression accounting for age and systolic blood pressure, 
these associations were no longer significant. 
Discussion
In this study, we have seen that 1) both pulmonary and 
systemic arteries are stiffer in COPD compared with con-
trols; 2) aortic PWV and pulmonary PWV are associated 
with different clinical parameters and biomarkers from one 
another; and 3) aortic but not pulmonary PWV is associated 
with ventricular hypertrophy.
Our finding of increased aortic stiffness is consistent with 
previous work demonstrating increased aortic PWV in those 
with COPD.33 In comparison with the previous studies that 
used carotid femoral PWV, the current study used MRI for 
the assessment of central aortic PWV. The two techniques 
have been shown to correlate well with one another, although 
carotid–femoral PWV significantly overestimates central 
aortic PWV due to the inclusion of the stiffer peripheral 
vessels in its calculation and inaccuracies in path length 
estimation.34–36 In addition, it excludes the ascending aorta 
from its measurement, with this playing a greater role in left 
ventricular remodeling compared with the rest of the aorta.37 
By its direct assessment of central aortic PWV, the current 
Table 2 Ventricular quantification, measures of PWV, and bio­
markers in the healthy control and COPD cohort
Healthy 
controls
COPD 
cohort
p-value
n 20 56
right ventricle
rVeDV (ml/m1.7) 58.7±12.1 53.6±11.2 0.09
rVesV (ml/m1.7) 22.2±8.2 21.9±7.4 0.87
rVsV (ml/m1.7) 36.6±5.9 31.7±7.0 0.007
rVeF (%) 63.3±7.9 59.6±7.9 0.08
rVM (g/m1.7) 14.7±2.4 15.2±3.2 0.50
rVMVr (g/ml) 0.25±0.04 0.29±0.05 0.012
left ventricle
lVeDV (ml/m1.7) 59.0±9.2 56.1±12.1 0.33
lVesV (ml/m1.7) 23.4±6.1 23.4±9.4 0.99
lVsV (ml/m1.7) 35.6±4.8 32.7±6.7 0.09
lVeF (%) 60.7±6.0 59.1±8.6 0.46
lVM (g/m1.7) 41.0±7.4 43.3±9.5 0.33
lVMVr (g/ml) 0.70±0.09 0.78±0.13 0.009
Pulse wave velocity
aortic PWV (m/s) 7.35±2.1 8.67±2.7 0.06
Pulmonary PWV (m/s) 1.76±0.7 2.63±1.3 0.006
Biomarkers
CMl (pg/ml) 210±84 260±191 0.27
MMP-9 (ng/ml) 50.2±18.9 121.1±72.2 ,0.001
FgF-23 (pg/ml) 26.2±18.2 22.9±6.8 0.27
CC-16 (ng/ml) 24.6±8.5 19.8±10.3 0.07
sPD (ng/ml) 9.12±5.41 16.90±12.71 0.001
hsCrP (mg/l) 2.49±2.84 6.41±7.68 0.002
Il-6 (pg/ml) 0.58±0.66 1.38±1.38 0.018
Fibrinogen (mg/ml) 4.01±1.09 3.89±1.52 0.73
TC (mmol/l) 5.92±0.92 5.41±1.18 0.09
hDl (mmol/l) 1.38±0.58 1.52±0.60 0.39
lDl (mmol/l) 2.93±1.21 2.58±1.44 0.35
Triglycerides (mmol/l) 1.86±0.99 1.60±0.96 0.31
hsTrop I (pg/ml) 0.92±0.49 2.27±1.90 ,0.001
nT-proBnP (pg/ml) 198±165 602±839 0.001
Abbreviations: CC-16, club cell secretory protein-16; CMl, carboxymethyllysine; 
FGF­23, fibroblast growth factor­23; HDL, high­density lipoprotein; hsCRP, high­
sensitivity C-reactive protein; hsTrop I, high-sensitivity troponin I; Il-6, interleukin-6; 
lDl, low-density lipoprotein; lVeDV, left ventricular end diastolic volume; lVeF, left 
ventricular ejection fraction; lVesV, left ventricular end systolic volume; lVM, left 
ventricular mass; lVMVr, left ventricular mass/volume ratio; lVsV, left ventricular 
stroke volume; MMP-9, metalloproteinase-9; nT-proBnP, n-terminal pro-brain 
natriuretic peptide; PWV, pulse wave velocity; rVeDV, right ventricular end 
diastolic volume; rVeF, right ventricular ejection fraction; rVesV, right ventricular 
end systolic volume; rVM, right ventricular mass; rVMVr, right ventricular mass/
volume ratio; rVsV, right ventricular stroke volume; sPD, surfactant protein D; TC, 
total cholesterol.
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study provides valuable insights into the interaction between 
central aortic stiffness and left ventricular remodeling. 
The underlying cause of the increased systemic arterial 
stiffness in COPD is still a topic of debate. While a previ-
ous association between aortic PWV and inflammatory 
markers has been described,38 other groups have found no 
such correlation.39,40 In the current study, we found that in 
those with COPD the aortic PWV was associated with age 
and blood pressure, but not with inflammatory markers. Our 
finding of a significant association between LVMVR – which 
is the earliest measure of concentric myocardial hypertro-
phic remodeling41 – and aortic PWV provides significant 
mechanistic insight into the interface between the pulmo-
nary and cardiovascular disease evident in COPD. As with 
increased aortic PWV, multiple studies have documented 
left ventricular hypertrophy in COPD, demonstrating both 
a high prevalence and significant implications for mortal-
ity in this group.42–44 While the association between PWV 
and left ventricular mass has been described in the general 
population,45,46 to the best of the authors’ knowledge, no 
studies have examined the role of the aortic arterial stiff-
ness as a linking mechanism in COPD. Indeed, a previous 
study ascribed the observed left ventricular hypertrophy to 
pulmonary hyperinflation, but did not measure or account 
for aortic stiffness.43 Given that LVMVR is a known risk 
factor for future cardiovascular events, this association may 
help explain both the increased cardiovascular risk in COPD 
and the beneficial effects in COPD of β-blockers – a known 
regressor of left ventricular mass.47–49
Increased pulmonary arterial stiffness in COPD has 
been previously reported both invasively on right heart 
catheterization and using pulsatility on MRI.4,15 Invasive 
pulmonary PWV has been demonstrated to correlate well 
with invasive pressure measurements in those with pulmo-
nary hypertension.50 Pulmonary PWV as measured on MRI 
provides the benefit of not requiring an invasive procedure 
to obtain direct information on the arterial wall. It also pro-
vides additional information over pulmonary pulsatility as 
this latter metric is a flow-dependent measure of the relative 
change in the area of the pulmonary artery throughout the 
cardiac cycle. Thus, assuming a steady pulmonary arterial 
wall stiffness, a fall in stroke volume will result in a fall 
in pulmonary pulsatility. As both a reduced stroke volume 
and a reduced pulmonary pulsatility have been described in 
COPD,15,51 pulmonary PWV is a useful measure to better 
interrogate pulmonary arterial remodeling.
Despite those with COPD having significantly elevated 
hsCRP, IL-6, MMP-9, NT-proBNP, and hsTrop I, none of 
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these markers showed any significant correlation with either 
aortic or pulmonary PWV. In the current study, we found 
no significant link between aortic and pulmonary PWV, 
with no overlap of clinical correlates or biomarkers. Thus, 
it would appear that the pulmonary vascular remodeling in 
COPD occurs separately to systemic arterial stiffening. Previ-
ous work has described pulmonary arterial stiffening to be 
significantly associated with exercise-induced elevations in 
pulmonary pressures;21,52 however, we found no link between 
this and RV remodeling; therefore, while the pressures may 
elevate in exercise, the clinical significance of this is uncer-
tain. Longitudinal studies will be required to determine the 
long-term implications of pulmonary arterial stiffening.
Given the lack of significant correlation between pulmonic 
and arterial stiffening and biomarkers, particularly the lack of 
association with inflammation, another link between COPD 
and arterial stiffening must also be considered. It has been 
previously demonstrated that the two strongest predictors of 
aortic PWV are age and blood pressure.8 The former of these 
reflects a gross marker of the total pulsatile cycles the aorta 
has undergone, while the latter reflects the pressure at which 
the walls have been distended during these cycles. Thus, 
COPD, with its higher heart rate secondary to lower stroke 
volumes as found in this and other studies,51,53 may accelerate 
arterial stiffening without the need for an inflammatory link. 
A study in a population free from cardiovascular disease has 
shown an elevated resting heart rate to be associated with 
increased aortic stiffness.54 In those with COPD, resting heart 
rate is associated with cardiovascular mortality, but a direct 
link between heart rate and arterial stiffness in COPD has yet 
to be evaluated.53,55 While elevated heart rate would affect 
the aortic and pulmonary circulation in a similar pattern, 
the underlying distending pressures in the two systems vary 
independently of one another; thus the two circulations may 
remodel at a different rate even with the same accelerating 
factor. Another alternative is the role of autonomic nervous 
system activation, which has been described in COPD and 
is known to be associated with PWV.56–58
There are some limitations to the current study. Patients 
with known coronary artery disease were excluded; thus, the 
results may not be representative of the wider COPD cohort in 
whom cardiovascular disease is common. Despite attempted 
matching, the controls were younger than those with COPD 
and more likely to be on treatment for hypertension although 
the blood pressures were well matched. As age is a significant 
contributor to PWV, this may have contributed to the differ-
ence between the two groups although our observations are 
concordant with the current literature.8 Unfortunately, due 
to the limited group sizes, particularly of the controls, the 
data did not meet assumptions required for the analysis of 
covariance; therefore, multiple variable modeling to account 
for these could not be performed. We also used two differ-
ent techniques for the MRI assessment of the aortic and 
pulmonary PWV, using a transit time method in the aorta 
and a flow area technique within the pulmonary artery. This 
was done as the former is more accurate in longer vessels 
such as the aorta;32 however, the short pulmonary artery 
is less amenable to this due to the rapid transit times, and 
prior work has shown the transit time within the pulmonary 
arteries to be less reproducible compared with the flow area 
technique.30 In addition, the two techniques demonstrate 
a reasonable agreement with one another minimizing the 
potential significance of this.59 Finally, if we had enrolled 
more severe hypoxic COPD patients in GOLD stages III/IV 
(ie, FEV,50%), then perhaps we would have seen more 
pronounced RV remodeling.
Conclusion
In conclusion, both aortic and pulmonary arterial stiffening 
occurs in COPD, but these processes are independent of one 
another with aortic but not pulmonary PWV, demonstrating 
a significant association with remodeling in the ventricle. 
Further work is warranted to determine whether this stiffen-
ing causes an increased morbidity and mortality and whether 
both can be targeted by similar pharmacological therapy or 
whether different strategies are required for each.
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Table S1 Intra-assay and interassay CoV for the biomarkers
Variable Manufacturer details Interassay  
(plate-to-
plate CoV, %)
Intra-assay 
(CoV, %)
surfactant protein D Bio-Techne, Minneapolis, Mn, Usa 9.1 4.0
Club cell protein-16 Cloud-Clone Corp., Katy, TX, Usa 5.4 10.4
Fibroblast growth factor-23 Cloud-Clone Corp. 9.6 6.2
hsCrP Kalon Biological ltd., guildford, UK 5.3 3.8
hsTrop I Quanterix, lexington, Ma, Usa 8.5 7.7
nT-proBnP Meso scale Discovery, rockville, MD, Usa 10.5 5.2
Fibrinogen Cusabio, houston, TX, Usa 4.1 3.1
Il-6 Meso scale Discovery 4.2 4.8
MMP-9 Bio-Techne 8.3 5.6
Carboxymethyllysine Cusabio 10.2 5.5
Abbreviations: CoV, coefficient of variation; hsCRP, high­sensitivity C­reactive protein; hsTrop I, high­sensitivity troponin I; IL­6, interleukin­6; MMP­9, metalloproteinase­9; 
nT-proBnP, n-terminal pro-brain natriuretic peptide.
Table S2 Correlation coefficients between aortic PWV and 
pulmonary PWV and demographic and ventricular measures
Variable Pulmonary 
PWV
Aortic PWV
ρ p-value ρ p-value
age 0.03 0.81 0.45 ,0.001
BMI (kg/m2) −0.28 0.036 −0.04 0.78
heart rate (bpm) 0.21 0.15 0.02 0.91
systolic BP (mmhg) 0.15 0.29 0.31 0.03
Diastolic BP (mmhg) 0.36 0.01 0.22 0.12
Pulse pressure (mmhg) 0.000 1 0.24 0.09
spO2 (%) −0.06 0.68 −0.07 0.64
Pack-years 0.004 0.98 −0.13 0.36
FeV1, % predicted −0.15 0.28 0.05 0.70
FVC, % predicted −0.06 0.64 −0.03 0.85
FeV1/FVC −0.17 0.21 0.07 0.64
KCO, % predicted −0.08 0.56 0.46 0.001
rlV, % predicted 0.25 0.08 −0.10 0.50
TlC, % predicted 0.28 0.046 −0.05 0.71
VC, % predicted −0.02 0.90 0.03 0.83
rlV/TlC 0.20 0.15 0.12 0.40
CMl −0.15 0.29 0.15 0.31
MMP-9 0.10 0.47 0.09 0.55
FgF-23 0.14 0.33 0.06 0.69
CC-16 −0.18 0.21 0.31 0.028
sPD −0.26 0.07 0.05 0.72
hsCrP −0.28 0.04 −0.007 0.96
Il-6 −0.26 0.07 −0.02 0.92
Fibrinogen 0.001 0.99 0.16 0.26
TC 0.28 0.044 0.33 0.019
hDl −0.12 0.40 0.06 0.70
lDl 0.15 0.28 0.32 0.023
Triglycerides −0.09 0.53 0.12 0.39
hsTrop I −0.15 0.29 0.17 0.23
Abbreviations: BMI, body mass index; BP, blood pressure; CC-16, club cell 
secretory protein-16; CMl, carboxymethyllysine; FeV1, forced expiratory volume 
in 1 second; FGF­23, fibroblast growth factor­23; FVC, forced vital capacity; HDL, 
high-density lipoprotein; hsCrP, high-sensitivity C-reactive protein; hsTrop I, high-
sensitivity troponin I; Il-6, interleukin-6; lDl, low-density lipoprotein; MMP-9, 
metalloproteinase-9; nT-proBnP, n-terminal pro-brain natriuretic peptide; PWV, 
pulse wave velocity; rlV, residual lung volume; sPD, surfactant protein D; TC, total 
cholesterol; TlC, total lung capacity; Va, alveolar volume.
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